Physician profile
Stephen A Morse
NPI 1801234729
$5,201.15
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $349 · 2021: $1,128 · 2022: $1,596 · 2023: $1,476 · 2024: $49.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $751.29 | 2019-2024 | Farxiga, Andexxa |
| Abbvie INC. | $639.22 | 2021-2023 | |
| Amgen INC. | $629.08 | 2019-2023 | Otezla, Repatha |
| Lilly USA, LLC | $551.82 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $500.12 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $376.40 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.32 | 2019-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $129.34 | 2022-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $114.22 | 2021-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.63 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $101.99 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $97.41 | 2022-2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $96.35 | 2020-2022 | |
| Corium, LLC | $87.95 | 2022-2023 | Azstarys |
| Pfizer INC. | $84.44 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $74.04 | 2021-2023 | |
| Exact Sciences Corporation | $66.78 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $62.93 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $61.89 | 2023 | |
| Alnylam Pharmaceuticals INC. | $55.44 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $54.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $42.88 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $37.50 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.16 | 2021-2022 | |
| Axsome Therapeutics, INC. | $27.67 | 2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $25.42 | 2019 | |
| Abbott Laboratories | $19.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.81 | 2022 | |
| Astellas Pharma US INC | $17.98 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.86 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.29 | 2023 | Unithroid |
| Xeris Pharmaceuticals, INC. | $15.54 | 2022 | |
| Medtronic, INC. | $14.88 | 2023 | Intellis Adaptivestim |
| Adlon Therapeutics L.P. | $12.06 | 2021 | |
| Supernus Pharmaceuticals, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.